Treatment and Management of Crimean-Congo Hemorrhagic Fever.

IF 0.8 4区医学 Q4 INFECTIOUS DISEASES

Journal of Vector Borne Diseases Pub Date : 2025-06-10 DOI:10.4103/jvbd.jvbd_18_25

Rukiyye Bulut, Bahar Kandemir, İbrahim Erayman, Pınar Belviranlı Keskin, Esma Kepenek Kurt

{"title":"Treatment and Management of Crimean-Congo Hemorrhagic Fever.","authors":"Rukiyye Bulut, Bahar Kandemir, İbrahim Erayman, Pınar Belviranlı Keskin, Esma Kepenek Kurt","doi":"10.4103/jvbd.jvbd_18_25","DOIUrl":null,"url":null,"abstract":"Background objectives: Crimean-Congo Hemorrhagic Fever (CCHF) is a tick-borne viral infection with a wide geographic distribution globally. The clinical severity of CCHF varies, with reported mortality rates reaching up to 60%. Despite its spread to new geographic areas and its potential to cause severe and fatal disease, no approved vaccine or antiviral treatment is currently available. Studies on the use of ribavirin for CCHF have yielded conflicting results. Consequently, many physicians manage CCHF patients with supportive care. In this study, we share the positive outcomes observed in CCHF patients who were managed exclusively with supportive treatment without the use of ribavirin.Methods: The epidemiological characteristics, laboratory results and treatment outcomes of patients with CCHF diagnosis followed up in our clinic between April 1, 2020, and September 31, 2023 were evaluated retrospectively.Results: The study included 20 patients (5 females and 15 male) with confirmed CCHF. Based on the Severity Scoring Index (SSI) scores, 7 patients with SSI 0-2 were classified as mild cases, 12 patients with SSI 3-9 as moderate cases, and 1 patient with SSI 10-13 as a severe case. No patients received ribavirin as part of their treatment. All patients were managed with supportive care, and no mortality was observed.Interpretation and conclusion: Supportive care remains the standard treatment for CCHF management. The effectiveness of ribavirin in CCHF remains unclear.","PeriodicalId":17660,"journal":{"name":"Journal of Vector Borne Diseases","volume":" ","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Vector Borne Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/jvbd.jvbd_18_25","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background objectives: Crimean-Congo Hemorrhagic Fever (CCHF) is a tick-borne viral infection with a wide geographic distribution globally. The clinical severity of CCHF varies, with reported mortality rates reaching up to 60%. Despite its spread to new geographic areas and its potential to cause severe and fatal disease, no approved vaccine or antiviral treatment is currently available. Studies on the use of ribavirin for CCHF have yielded conflicting results. Consequently, many physicians manage CCHF patients with supportive care. In this study, we share the positive outcomes observed in CCHF patients who were managed exclusively with supportive treatment without the use of ribavirin.

Methods: The epidemiological characteristics, laboratory results and treatment outcomes of patients with CCHF diagnosis followed up in our clinic between April 1, 2020, and September 31, 2023 were evaluated retrospectively.

Results: The study included 20 patients (5 females and 15 male) with confirmed CCHF. Based on the Severity Scoring Index (SSI) scores, 7 patients with SSI 0-2 were classified as mild cases, 12 patients with SSI 3-9 as moderate cases, and 1 patient with SSI 10-13 as a severe case. No patients received ribavirin as part of their treatment. All patients were managed with supportive care, and no mortality was observed.

Interpretation and conclusion: Supportive care remains the standard treatment for CCHF management. The effectiveness of ribavirin in CCHF remains unclear.

查看原文本刊更多论文

克里米亚-刚果出血热的治疗和管理。

背景目的：克里米亚-刚果出血热（CCHF）是一种蜱传病毒感染，在全球具有广泛的地理分布。CCHF的临床严重程度各不相同，据报道死亡率高达60%。尽管它传播到新的地理区域，并有可能导致严重和致命的疾病，但目前还没有获得批准的疫苗或抗病毒治疗。关于利巴韦林治疗慢性心力衰竭的研究产生了相互矛盾的结果。因此，许多医生对CCHF患者进行支持性治疗。在这项研究中，我们分享了在CCHF患者中观察到的积极结果，这些患者只接受支持治疗而不使用利巴韦林。方法：回顾性分析我院2020年4月1日至2023年9月31日随访的CCHF确诊患者的流行病学特征、实验室检查结果及治疗结果。结果：本研究纳入确诊CCHF患者20例（女5例，男15例）。根据严重程度评分指数（SSI）评分，7例SSI 0-2分为轻度，12例SSI 3-9分为中度，1例SSI 10-13分为重度。没有患者接受利巴韦林作为治疗的一部分。所有患者均接受支持性治疗，未观察到死亡。解释和结论：支持治疗仍然是CCHF治疗的标准治疗方法。利巴韦林治疗慢性心力衰竭的有效性尚不清楚。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Vector Borne Diseases INFECTIOUS DISEASES-PARASITOLOGY

CiteScore

0.90

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： National Institute of Malaria Research on behalf of Indian Council of Medical Research (ICMR) publishes the Journal of Vector Borne Diseases. This Journal was earlier published as the Indian Journal of Malariology, a peer reviewed and open access biomedical journal in the field of vector borne diseases. The Journal publishes review articles, original research articles, short research communications, case reports of prime importance, letters to the editor in the field of vector borne diseases and their control.